Role of caveolae and caveolins in health and disease

Physiological Reviews

Volumn 84, Issue 4, 2004, Pages 1341-1379

  Cohen, Alex W ^a   Hnasko, Robert ^a   Schubert, William ^a   Lisanti, Michael P ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; ALBUMIN; CALSEQUESTRIN; CAVEOLIN 1; CAVEOLIN 2; CAVEOLIN 3; CD36 ANTIGEN; CLATHRIN; LIPOCORTIN 2; MEMBRANE LIPID; MYOSIN; NITRIC OXIDE; PORIN; VESICULAR TRANSPORT PROTEIN;

ATHEROSCLEROSIS; CARCINOGENESIS; CARDIOVASCULAR DISEASE; CAVEOLA; CELL FUNCTION; CELL ORGANELLE; CELL TRANSFORMATION; DEGENERATIVE DISEASE; DIABETES MELLITUS; GLUCOSE METABOLISM; HYPERTROPHIC CARDIOMYOPATHY; LIPID COMPOSITION; LIPID STORAGE; LUNG FIBROSIS; MALIGNANT NEOPLASTIC DISEASE; MUSCULAR DYSTROPHY; NUCLEOTIDE SEQUENCE; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN INTERACTION; PROTEOMICS; REVIEW; SIGNAL TRANSDUCTION;

AMINO ACID SEQUENCE; ANIMALS; CAVEOLAE; CAVEOLIN 1; CAVEOLINS; DISEASE; HUMANS; MOLECULAR SEQUENCE DATA; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION;

EID: 4644224284     PISSN: 00319333     EISSN: None     Source Type: Journal    
DOI: 10.1152/physrev.00046.2003     Document Type: Review

References (293)

1. Abrami L and van Der Goot FG. Plasma membrane microdomains act as concentration platforms to facilitate intoxication by aerolysin. J Cell Biol 147: 175-184, 1999.
2. Arbuzova A, Wang L, Wang J, Hangyas-Mihalyne G, Murray D, Honig B, and McLaughlin S. Membrane binding of peptides containing both basic and aromatic residues. Experimental studies with peptides corresponding to the scaffolding region of caveolin and the effector region of MARCKS. Biochemistry 39: 10330-10339, 2000.
3. Baorto DM, Gao Z, Malaviya R, Dustin ML, van der Merwe A, Lublin DM, and Abraham SN. Survival of FimH-expressing enterobacteria in macrophages relies on glycolipid traffic. Nature 389: 636-639, 1997.
4. Bender FC, Reymond MA, Bron C, and Quest AF. Caveolin-1 levels are down-regulated in human colon tumors, and ectopic expression of caveolin-1 in colon carcinoma cell lines reduces cell tumorigenicity. Cancer Res 60: 5870-5878, 2000.
5. Betz RC, Schoser BG, Kasper D, Ricker K, Ramirez A, Stein V, Torbergsen T, Lee YA, Nothen MM, Wienker TF, Malin JP, Propping P, Reis A, Mortier W, Jentsch TJ, Vorgerd M, and Kubisch C. Mutations in CAV3 cause mechanical hyperirritability of skeletal muscle in rippling muscle disease. Nat Genet 28: 218-219, 2001.
6. Bickel PE, Scherer PE, Schnitzer JE, Oh P, Lisanti MP, and Lodish HF. Flotillin and epidermal surface antigen define a new family of caveolae-associated integral membrane proteins. J Biol Chem 272: 13793-13802, 1997.
7. Biedler JL and Spengler BA. Reverse transformation of multidrug-resistant cells. Cancer Metastasis Rev 13: 191-207, 1994.
8. Bist A, Fielding PE, and Fielding CJ. Two sterol regulatory element-like sequences mediate up-regulation of caveolin gene transcription in response to low density lipoprotein free cholesterol. Proc Natl Acad Sci USA 94: 10693-10698, 1997.
9. Bluher M, Michael MD, Peroni OD, Ueki K, Carter N, Kahn BB, and Kahn CR. Adipose tissue selective insulin receptor knockout protects against obesity and obesity-related glucose intolerance. Dev Cell 3: 25-38, 2002.
10. Boesze-Battaglia K, Dispoto J, and Kahoe MA. Association of a photoreceptor-specific tetraspanin protein, ROM-1, with triton X-100-resistant membrane rafts from rod outer segment disk membranes. J Biol Chem 277: 41843-41849, 2002.
11. Bonilla E, Fishbeck K, and Schotland D. Freeze-fracture studies of muscle caveolae in human muscular dystrophy. Am J Pathol 104: 167-173, 1981.
12. Bosch I and Croop J. P-glycoprotein multidrug resistance and cancer. Biochim Biophys Acta 1288: F37-F54, 1996.
13. Bras AM and Ketley JM. Transcellular translocation of Campylobacter jejuni across human polarised epithelial monolayers. FEMS Microbiol Lett 179: 209-215, 1999.
14. Brasaemle DL, Barber T, Wolins NE, Serrero G, Blanchette-Mackie EJ, and Londos C. Adipose differentiation-related protein is an ubiquitously expressed lipid storage droplet-associated protein. J Lipid Res 38: 2249-2263, 1997.
15. Brasaemle DL, Levin DM, Adler-Wailes DC, and Londos C. The lipolytic stimulation of 3T3-L1 adipocytes promotes the translocation of hormone-sensitive lipase to the surfaces of lipid storage droplets. Biochim Biophys Acta 1483: 251-262, 2000.
16. Campbell SM, Crowe SM, and Mak J. Lipid rafts and HIV-1: from viral entry to assembly of progeny virions. J Clin Virol 22: 217-227, 2001.
17. Cao G, Yang G, Timme TL, Saika T, Truong LD, Satoh T, Goltsov A, Park SH, Men T, Kusaka N, Tian W, Ren C, Wang H, Kadmon D, Cai WW, Chinault AC, Boone TB, Bradley A, and Thompson TC. Disruption of the caveolin-1 gene impairs renal calcium reabsorption and leads to hypercalciuria and urolithiasis. Am J Pathol 162: 1241-1248, 2003.
18. Capozza F, Williams TM, Schubert W, McClain S, Bouzahzah B, Sotgia F, and Lisanti MP. Absence of caveolin-1 sensitizes mouse skin to carcinogen-induced epidermal hyperplasia and tumor formation. Am J Pathol 162: 2029-2039, 2003.
19. Carbone I, Bruno C, Sotgia F, Bado M, Broda P, Masetti E, Panella A, Zara F, Bricarelli FD, Cordone G, Lisanti MP, and Minetti C. Mutation in the CAV3 gene causes partial caveolin-3 deficiency and hyperCKemia. Neurology 54: 1373-1376, 2000.
20. Chan SY, Empig CJ, Welte FJ, Speck RF, Schmaljohn A, Kreisberg JF, and Goldsmith MA. Folate receptor-alpha is a cofactor for cellular entry by Marburg and Ebola viruses. Cell 106: 117-126, 2001.
21. Chen Y and Norkin LC. Extracellular simian virus 40 transmits a signal that promotes virus enclosure within caveolae. Exp Cell Res 246: 83-90, 1999.
22. Chiang SH, Baumann CA, Kanzaki M, Thurmond DC, Watson RT, Neudauer CL, Macara IG, Pessin JE, and Saltiel AR. Insulin-stimulated GLUT4 translocation requires the CAP-dependent activation of TC10. Nature 410: 944-948, 2001.
23. Christiani DC and Wang XR. Respiratory effects of long-term exposure to cotton dust. Curr Opin Pulm Med 9: 151-155, 2003.
24. Clifford GM, Kraemer FB, Yeaman SJ, and Vernon RG. Translocation of hormone-sensitive lipase and perilipin upon lipolytic stimulation during the lactation cycle of the rat. Metabolism 50: 1264-1269, 2001.
25. Clifford GM, Londos C, Kraemer FB, Vernon RG, and Yeaman SJ. Translocation of hormone-sensitive lipase and perilipin upon lipolytic stimulation of rat adipocytes. J Biol Chem 275: 5011-5015, 2000.
26. Clifford GM, McCormick DK, Vernon RG, and Yeaman SJ. Translocation of perilipin and hormone-sensitive lipase in response to lipolytic hormones. Biochem Soc Trans 25: S672, 1997.
27. Cohen AW, Combs TP, Scherer PE, and Lisanti MP. Role of caveolin and caveolae in insulin signaling and diabetes. Am J Physiol Endocrinol Metab 285: E1151-E1160, 2003.
28. Cohen AW, Park DS, Woodman SE, Williams TM, Chandra M, Shirani J, Pereira de Souza A, Kitsis RN, Russell RG, Weiss LM, Tang B, Jelicks LA, Factor SM, Shtutin V, Tanowitz HB, and Lisanti MP. Caveolin-1 null mice develop cardiac hypertrophy with hyperactivation of p42/44 MAP kinase in cardiac fibroblasts. Am J Physiol Cell Physiol 284: C457-C474, 2003.
29. Cohen AW, Razani B, Schubert W, Williams TM, Wang XB, Iyengar P, Brasaemle DL, Scherer PE, and Lisanti MP. Role of caveolin-1 in the modulation of lipolysis and lipid droplet formation. Diabetes 53: 1261-1270, 2004.
30. Cohen AW, Razani B, Wang XB, Combs TP, Williams TM, Scherer PE, and Lisanti MP. Caveolin-1-deficient mice show insulin resistance and defective insulin receptor protein expression in adipose tissue. Am J Physiol Cell Physiol 285: C222-C235, 2003.
31. Corley-Mastick C, Brady MJ, and Saltiel AR. Insulin stimulates the tyrosine phosphorylation of caveolin. J Cell Biol 129: 1523-1531, 1995.
32. Corley-Mastick C and Saltiel AR. Insulin-stimulated tyrosine phosphorylation of caveolin is specific for the differentiated adipocyte phenotype in 3T3-L1 cells. J Biol Chem 272: 20706-20714, 1997.
33. Couet J, Li S, Okamoto T, Ikezu T, and Lisanti MP. Identification of peptide and protein ligands for the caveolin-scaffolding domain. Implications for the interaction of caveolin with caveolae-associated proteins. J Biol Chem 272: 6525-6533, 1997.
34. Couet J, Li S, Okamoto T, Scherer PS, and Lisanti MP. Molecular and cellular biology of caveolae: paradoxes and plasticities. Trends Cardiovasc Med 7: 103-110, 1997.
35. Couet J, Sargiacomo M, and Lisanti MP. Interaction of a receptor tyrosine kinase, EGF-R, with caveolins. Caveolin binding negatively regulates tyrosine and serine/threonine kinase activities. J Biol Chem 272: 30429-30438, 1997.
36. Cui J, Rohr LR, Swanson G, Speights VO, Maxwell T, and Brothman AR. Hypermethylation of the caveolin-1 gene promoter in prostate cancer. Prostate 46: 249-256, 2001.
37. Dauty E, Remy JS, Zuber G, and Behr JP. Intracellular delivery of nanometric DNA particles via the folate receptor. Bioconjug Chem 13: 831-839, 2002.
38. De Marco MC, Kremer L, Albar JP, Martinez-Menarguez JA, Ballesta J, Garcia-Lopez MA, Marazuela M, Puertollano R, and Alonso MA. BENE, a novel raft-associated protein of the MAL proteolipid family, interacts with caveolin-1 in human endothelial-like ECV304 cells. J Biol Chem 276: 23009-23017, 2001.
39. Dietzen DJ, Hastings WR, and Lublin DM. Caveolin is palmitoylated on multiple cysteine residues: palmitoylation is not necessary for localization of caveolin to caveolae. J Biol Chem 270: 6838-6842, 1995.
40. Drab M, Verkade P, Elger M, Kasper M, Lohn M, Lauterbach B, Menne J, Lindschau C, Mende F, Luft FC, Schedl A, Haller H, and Kurzchalia TV. Loss of caveolae, vascular dysfunction, and pulmonary defects in caveolin-1 gene-disrupted mice. Science 293: 2449-2452, 2001.
41. Dryja TT, Hahn LB, Kajiwara K, and Berson EL. Dominant and digenic mutations in the peripherin/RDS and ROM1 genes in retinitis pigmentosa. Invest Ophthalmol Vis Sci 38: 1972-1982, 1997.
42. Dupree P, Parton RG, Raposo G, Kurzchalia TV, and Simons K. Caveolae and sorting of the trans-Golgi network of epithelial cells. EMBO J 12: 1597-1605, 1993.
43. Egan JJ, Greenberg AS, Chang MK, Wek SA, Moos MC Jr, and Londos C. Mechanism of hormone-stimulated lipolysis in adipocytes: translocation of hormone-sensitive lipase to the lipid storage droplet. Proc Natl Acad Sci USA 89: 8537-8541, 1992.
44. Elliott MH, Fliesler SJ, and Ghalayini AJ. Cholesterol-dependent association of caveolin-1 with the transducin alpha subunit in bovine photoreceptor rod outer segments: disruption by cyclodextrin and guanosine 5′-O-(3-thiotriphosphate). Biochemistry 42: 7892-7903, 2003.
45. Emery AE. The muscular dystrophies. Lancet 359: 687-695, 2002.
46. Engelman JA, Chu C, Lin A, Jo H, Ikezu T, Okamoto T, Kohtz DS, and Lisanti MP. Caveolin-mediated regulation of signaling along the p42/44 MAP kinase cascade in vivo. A role for the caveolin-scaffolding domain. FEBS Lett 428: 205-211, 1998.
47. Engelman JA, Lee RJ, Karnezis A, Bearss DJ, Webster M, Siegel P, Muller WJ, Windle JJ, Pestell RG, and Lisanti MP. Reciprocal regulation of Neu tyrosine kinase activity and caveolin-1 protein expression in vitro and in vivo. Implications for mammary tumorigenesis. J Biol Chem 273: 20448-20455, 1998.
48. Engelman JA, Wycoff CC, Yasuhara S, Song KS, Okamoto T, and Lisanti MP. Recombinant expression of caveolin-1 in oncogenically transformed cells abrogates anchorage-independent growth. J Biol Chem 272: 16374-16381, 1997.
49. Engelman JA, Zhang XL, Galbiati F, and Lisanti MP. Chromosomal localization, genomic organization, and developmental expression of the murine caveolin gene family (Cav-1, -2, and -3). Cav-1 and Cav-2 genes map to a known tumor suppressor locus (6-A2/7q31). FEBS Lett 429: 330-336, 1998.
50. Engelman JA, Zhang XL, and Lisanti MP. Genes encoding human caveolin-1 and -2 are co-localized to the D7S522 locus (7q31.1), a known fragile site (FRA7G) that is frequently deleted in human cancers. FEBS Lett 436: 403-410, 1998.
51. Engelman JA, Zhang XL, and Lisanti MP. Sequence and detailed organization of the human caveolin-1 and -2 genes located near the D7S522 locus (7q31.1). Methylation of a CpG island in the 5′ promoter region of the caveolin-1 gene in human breast cancer cell lines. FEBS Lett 448: 221-930, 1999.
52. Engelman JA, Zhang XL, Pestell RG, and Lisanti MP. p42/44 MAP kinase-dependent and -independent signaling pathways regulate caveolin-1 gene expression. J Biol Chem 274: 32333-32341, 1999.
53. Fan JY, Carpentier JL, van Obberghen E, Grunfeld C, Gorden P, and Orci L. Morphological changes of the 3T3-L1 fibroblast plasma membrane upon differentiation to the adipocyte form. J Cell Sci 61: 219-230, 1983.
54. Fellrath JM and du Bois RM. Idiopathic pulmonary fibrosis/cryptogenic fibrosing alveolitis. Clin Exp Med 3: 65-83, 2003.
55. Feron O, Belhhassen L, Kobzik L, Smith TW, Kelly RA, and Michel T. Endothelial nitric oxide synthase targeting to caveolae. Specific interactions with caveolin isoforms in cardiac myocytes and endothelial cells. J Biol Chem 271: 22810-22814, 1996.
56. Fidler IJ. Critical determinants of metastasis. Semin Cancer Biol 12: 89-96, 2002.
57. Fiedler K, Parton RG, Kellner R, Etzold T, and Simons K. VIP36, a novel component of glycolipid rafts and exocytic carrier vesicles in epithelial cells. EMBO J 13: 1729-1740, 1994.
58. Fielding CJ, Bist A, and Fielding PE. Caveolin mRNA levels are up-regulated by free cholesterol and down-regulated by oxysterols in fibroblast monolayers. Proc Natl Acad Sci USA 94: 3753-3758, 1997.
59. Fine SW, Lisanti MP, Galbiati F, and Li M. Elevated expression of caveolin-1 in adenocarcinoma of the colon. Am J Clin Pathol 115: 719-724, 2001.
60. Fiucci G, Ravid D, Reich R, and Liscovitch M. Caveolin-1 inhibits anchorage-independent growth, anoikis and invasiveness in MCF-7 human breast cancer cells. Oncogene 21: 2365-2375, 2002.
61. Flynn MR and Susi P. Engineering controls for selected silica and dust exposures in the construction industry - a review. Appl Occup Environ Hyg 18: 268-277, 2003.
62. Frank PG, Lee H, Park DS, Tandon NN, Scherer PE, and Lisanti MT. Genetic ablation of caveolin-1 confers protection against atherosclerosis. Arterioscler Thromb Vasc Biol 24: 98-105, 2004.
63. Frank PG, Marcel YL, Connelly MA, Lublin DM, Franklin V, Williams DL, and Lisanti MP. Stabilization of caveolin-1 by cellular cholesterol and scavenger receptor class B type I. Biochemistry 41: 11931-11940, 2002.
64. Fujimoto T, Kogo H, Ishiguro K, Tauchi K, and Nomura R. Caveolin-2 is targeted to lipid droplets, a new "membrane domain" in the cell. J Cell Biol 152: 1079-1085, 2001.
65. Fujimoto T, Kogo H, Nomura R, and Une T. Isoforms of caveolin-1 and caveolar structure. J Cell Sci 113: 3509-3517, 2000.
66. Furuchi T and Anderson RGW. Cholesterol depletion of caveolae causes hyperactivation of extracellular signal-related kinase (ERK). J Biol Chem 273: 21099-21104, 1998.
67. Galbiati F, Engelman JA, Volonte D, Zhang XL, Minetti C, Li M, Hou H Jr, Kneitz B, Edelmann W, and Lisanti MP. Caveolin-3 null mice show a loss of caveolae, changes in the microdomain distribution of the dystrophin-glycoprotein complex, and T-tubule abnormalities. J Biol Chem 276: 21425-21433, 2001.
68. Galbiati F, Volonte D, Chu JB, Li M, Fine SW, Fu M, Bermudez J, Pedemonte M, Weidenheim KM, Pestell RG, Minetti C, and Lisanti MP. Transgenic overexpression of caveolin-3 in skeletal muscle fibers induces a Duchenne-like muscular dystrophy phenotype. Proc Natl Acad Sci USA 97: 9689-9694, 2000.
69. Galbiati F, Volonte D, Engelman JA, Scherer PE, and Lisanti MP. Targeted down-regulation of caveolin-3 is sufficient to inhibit myotube formation in differentiating C2C12 myoblasts. Transient activation of p38 mitogen-activated protein kinase is required for induction of caveolin-3 expression and subsequent myotube formation. J Biol Chem 274: 30315-30321, 1999.
70. Galblati F, Volonté D, Engelman JA, Watanabe G, Burk R, Pestell R, and Lisanti MP. Targeted down-regulation of caveolin-1 is sufficient to drive cell transformation and hyperactivate the p42/44 MAP kinase cascade. EMBO J 17: 6633-6648, 1998.
71. Galblati F, Volonte D, Minetti C, Bregman DB, and Lisanti MP. Limb-girdle muscular dystrophy (LGMD-1C) mutants of caveolin-3 undergo ubiquitination and proteasomal degradation. Treatment with proteasomal inhibitors blocks the dominant negative effect of LGMD-1C mutants and rescues wild-type caveolin-3. J Biol Chem 275: 37702-37711, 2000.
72. Galbiati F, Volonte D, Minetti C, Chu JB, and Lisanti MP. Phenotypic behavior of caveolin-3 mutations that cause autosomal dominant limb girdle muscular dystrophy (LGMD-1C). Retention of LGMD-1C caveolin-3 mutants within the Golgi complex. J Biol Chem 274: 25632-25641, 1999.
73. Gatfield J and Pieters J. Essential role for cholesterol in entry of mycobacteria into macrophages. Science 288: 1647-1650, 2000.
74. Ghitescu L, Fixman A, Simonescu M, and Simonescu N. Specific binding sites for albumin restricted to plasmalemmal vesicles of continuous capillary endothelium: receptor-mediated transcytosis. J Cell Biol 102: 1304-1311, 1986.
75. Glenney JR. The sequence of human caveolin reveals identity with VIP 21, a component of transport vesicles. FEBS Lett 314: 45-48, 1992.
76. Glenney JR Jr. Tyrosine phosphorylation of a 22-kDa protein is correlated with transformation by Rous sarcoma virus. J Biol Chem 264: 20163-20166, 1989.
77. Glenney JR Jr and Zokas L. Novel tyrosine kinase substrates from Rous sarcoma virus-transformed cells are present in the membrane skeleton. J Cell Biol 108: 2401-2408, 1989.
78. Goldberg RI, Smith RM, and Jarett L. Insulin and alpha 2-macroglobulin-methylamine undergo endocytosis by different mechanisms in rat adipocytes. II. Comparison of intracellular events. J Cell Physiol 133: 213-218, 1987.
79. Goldberg RI, Smith RM, and Jarett L. Insulin and alpha-2 macroglobulin undergo endocytosis by different mechanisms in rat adipocytes. J Cell Physiol 133: 203-212, 1987.
80. Gordon VM, Nelson KL, Buckley JT, Stevens VL, Tweten RK, Elwood PC, and Leppla SH. Clostridium septicum alpha toxin uses glycosylphosphatidylinositol- anchored protein receptors. J Biol Chem 274: 27274-27280, 1999.
81. Graf GA, Connell PM, van der Westhuyzen DR, and Smart EJ. The class B, type I scavenger receptor promotes the selective uptake of high density lipoprotein cholesterol ethers into cavoelae. J Biol Chem 274: 12043-12048, 1999.
82. Greenberg AS, Egan JJ, Wek SA, Garty NB, Blanchette-Mackie EJ, and Londos C. Perilipin, a major hormonally regulated adipocyte-specific phosphoprotein associated with the periphery of lipid storage droplets. J Biol Chem 266: 11341-11346, 1991.
83. Griffoni C, Spisni E, Santi S, Riccio M, Guarnieri T, and Tomasi V. Knockdown of caveolin-1 by antisense oligonucleotides impairs angiogenesis in vitro and in vivo. Biochem Biophys Res Commun 276: 756-761, 2000.
84. Gustavsson J, Parpal S, Karlsson M, Ramsing C, Thorn H, Borg M, Lindroth M, Peterson KH, Magnusson KE, and Stralfors P. Localization of the insulin receptor in caveolae of adipocyte plasma membrane. FASEB J 13: 1961-1971, 1999.
85. Haemmerle G, Zimmermann R, Strauss JG, Kratky D, Riederer M, Knipping G, and Zechner R. Hormone-sensitive lipase deficiency in mice changes the plasma lipid profile by affecting the tissue-specific expression pattern of lipoprotein lipase in adipose tissue and muscle. J Biol Chem 277: 12946-12952, 2002.
86. Hagiwara Y, Sasaoka T, Araishi K, Imamura M, Yorifuji H, Nonaka I, Ozawa E, and Kikuchi T. Caveolin-3 deficiency causes muscle degeneration in mice. Hum Mol Genet 9: 3047-3054, 2000.
87. Hassan GS, Jasmin JF, Schubert W, Frank PG, and Lisanti MP. Caveolin-1 deficiency stimulates neointima formation during vascular injury. Biochemistry 43: 8312-8321, 2004.
88. Hayashi K, Matsuda S, Machida K, Yamamoto T, Fukuda Y, Nimura Y, Hayakawa T, and Hamaguchi M. Invasion activating caveolin-1 mutation in human scirrhous breast cancers. Cancer Res 61: 2361-2364, 2001.
89. Hayashi T, Arimura T, Ueda K, Shibata H, Hohda S, Takahashi M, Hori H, Koga Y, Oka N, Imaizumi T, Yasunami M, and Kimura A. Identification and functional analysis of a caveolin-3 mutation associated with familial hypertrophic cardiomyopathy. Biochem Biophys Res Commun 313: 178-184, 2004.
90. Henderson RM, Edwardson JM, Geisse NA, and Saslowsky DE. Lipid rafts: feeling is believing. News Physiol Sci 19: 39-43, 2004.
91. Henley JR, Krueger EW, Oswald BJ, and McNiven MA. Dynamin-mediated internalization of caveolae. J Cell Biol 141: 85-99, 1998.
92. Herrmann R, Straub V, Blank M, Kutzick C, Franke N, Jacob EN, Lenard HG, Kroger S, and Voit T. Dissociation of the dystroglycan complex in caveolin-3-deficient limb girdle muscular dystrophy. Hum Mol Genet 9: 2335-2340, 2000.
93. Hims MM, Diager SP, and Inglehearn CF. Retinitis pigmentosa: genes, proteins and prospects. Dev Ophthalmol 37: 109-125, 2003.
94. Hino M, Doihara H, Kobayashi K, Aoe M, and Shimizu N. Caveolin-1 as tumor suppressor gene in breast cancer. Surg Today 33: 486-490, 2003.
95. Ho CC, Huang PH, Huang HY, Chen YH, Yang PC, and Hsu SM. Up-regulated caveolin-1 accentuates the metastasis capability of lung adenocarcinoma by inducing filopodia formation. Am J Pathol 161: 1647-1656, 2002.
96. Hoffman EP, Brown RH Jr, and Kunkel LM. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 51: 919-928, 1987.
97. Hoffman EP and Kunkel LM. Dystrophin abnormalities in Duchenne/Becker muscular dystrophy. Neuron 2: 1019-1029, 1989.
98. Horejsi V. Transmembrane adaptor proteins in membrane microdomains: important regulators of immunoreceptor signaling. Immunol Lett 92: 43-49, 2004.
99. Hurlstone AF, Reid G, Reeves JR, Fraser J, Strathdee G, Rahilly M, Parkinson EK, and Black DM. Analysis of the CAVEOLIN-1 gene at human chromosome 7q31.1 in primary tumours and tumour-derived cell lines. Oncogene 18: 1881-1890, 1999.
100. Imamura T, Haruta T, Takata Y, Usui I, Iwata M, Ishihara H, Ishiki M, Ishibashi O, Ueno E, Sasaoka T, and Kobayashi M. Involvement of heat shock protein 90 in the degradation of mutant insulin receptors by the proteasome. J Biol Chem 273: 11183-11188, 1998.
101. Imamura T, Takata Y, Sasaoka T, Takada Y, Morioka H, Haruta T, Sawa T, Iwanishi M, Hu YG, and Suzuki Y. Two naturally occurring mutations in the kinase domain of insulin receptor accelerate degradation of the insulin receptor and impair the kinase activity. J Biol Chem 269: 31019-31027, 1994.
102. Ishikawa H. Formation of elaborate networks of T-system tubules in cultured skeletal muscle with special reference to the T-system formation. J Cell Biol 38: 51-66, 1968.
103. Iwanishi M, Haruta T, Takata Y, Ishibashi O, Sasaoka T, Egawa K, Imamura T, Naitou K, Itazu T, and Kobayashi M. A mutation (Trp1193→Leu1193) in the tyrosine kinase domain of the insulin receptor associated with type A syndrome of insulin resistance. Diabetologia 36: 414-422, 1993.
104. Jagannadham MV, Sharadadevi A, and Nagaraj R. Effects of deleting a tripeptide sequence observed in muscular dystrophy patients on the conformation of synthetic peptides corresponding to the scaffolding domain of caveolin-3. Biochem Biophys Res Commun 298: 203-206, 2002.
105. Jenkins RB, Qian J, Lee HK, Huang H, Hirasawa K, Bostwick DG, Proffitt J, Wilber K, Lieber MM, Liu W, and Smith DI. A molecular cytogenetic analysis of 7q31 in prostate cancer. Cancer Res 58: 759-766, 1998.
106. Kajiwara K, Berson EL, and Dryja TP. Digenic retinitis pigmentosa due to mutations at the unlinked peripherin/RDS and ROM1 loci. Science 264: 1604-1608, 1994.
107. Kalra P and Tigas S. Regulation of lipolysis: natriuretic peptides and the development of cachexia. Int J Cardiol 85: 125, 2002.
108. Karnauchow TM, Tolson DL, Harrison BA, Altman E, Lublin DM, and Dimock K. The HeLa cell receptor for enterovirus 70 is decay-accelerating factor (CD55). J Virol 70: 5143-5152, 1996.
109. Kato K, Hida Y, Miyamoto M, Hashida H, Shinohara T, Itoh T, Okushiba S, Kondo S, and Katoh H. Overexpression of caveolin-1 in esophageal squamous cell carcinoma correlates with lymph node metastasis and pathologic stage. Cancer 94: 929-933, 2002.
110. Kerr J, Leary JA, Hurst T, Shih YC, Antalis TM, Friedlander M, Crawford E, Khoo SK, Ward B, and Chenevix-Trench G. Allelic loss on chromosome 7q in ovarian adenocarcinomas: two critical regions and a rearrangement of the PLANH1 locus. Oncogene 13: 1815-1818, 1996.
111. Kim MJ, Dawes J, and Jessup W. Transendothelial transport of modified low-density lipoproteins. Atherosclerosis 108: 5-17, 1994.
112. Kimura A, Mora S, Shigematsu S, Pessin JE, and Saltiel AR. The insulin receptor catalyzes the tyrosine phosphorylation of caveolin-1. J Biol Chem 277: 30153-30158, 2002.
113. Kogo H, Ishiguro K, Kuwaki S, and Fujimoto T. Identification of a splice variant of mouse caveolin-2 mRNA encoding an isoform lacking the C-terminal domain. Arch Biochem Biophys 401: 108-114, 2002.
114. Koleske AJ, Baltimore D, and Lisanti MP. Reduction of caveolin and caveolae in oncogenically transformed cells. Proc Natl Acad Sci USA 92: 1381-1385, 1995.
115. Kurzchalia T, Dupree P, Parton RG, Kellner R, Virta H, Lehnert M, and Simons K. VIP 21, A 21-kD membrane protein is an integral component of trans-Golgi-network-derived transport vesicles. J Cell Biol 118: 1003-1014, 1992.
116. Kurzchalia TV and Parton RG. Membrane microdomains and caveolae. Curr Opin Cell Biol 11: 424-431, 1999.
117. Lai EC. Lipid rafts make for slippery platforms. J Cell Biol 162: 365-370, 2003.
118. Lauer S, VanWye J, Harrison T, McManus H, Samuel BU, Hiller NL, Mohandas N, and Haldar K. Vacuolar uptake of host components, and a role for cholesterol and sphingomyelin in malarial infection. EMBO J 19: 3556-3564, 2000.
119. Lavie Y, Fiucci G, and Liscovitch M. Up-regulation of caveolae and caveolar constituents in multidrug-resistant cancer cells. J Biol Chem 273: 32380-32383, 1998.
120. Lavie Y, Fiucci G, and Liscovitch M. Upregulation of caveolin in multidrug resistant cancer cells: functional implications. Adv Drug Deliv Rev 49: 317-323, 2001.
121. Lee H, Park DS, Razani B, Russell RG, Pestell RG, and Lisanti MP. Caveolin-1 mutations (P132L and null) and the pathogenesis of breast cancer: caveolin-1 (P132L) behaves in a dominant-negative manner and caveolin-1 (-/-) null mice show mammary epithelial cell hyperplasia. Am J Pathol 161: 1357-1369, 2002.
122. Lee H, Volonte D, Galbiati F, Iyengar P, Lublin DM, Bregman DB, Wilson MT, Campos-Gonzalez R, Bouzahzah B, Pestell RG, Scherer PE, and Lisanti MP. Constitutive and growth factor-regulated phosphorylation of caveolin-1 occurs at the same site (Tyr-14) in vivo: identification of a c-Src/Cav-1/Grb7 signaling cassette. Mol Endocrinol 14: 1750-1775, 2000.
123. Lee SW, Reimer CL, Oh P, Campbell DB, and Schnitzer JE. Tumor cell growth inhibition by caveolin re-expression in human breast cancer cells. Oncogene 16: 1391-1397, 1998.
124. Li S, Couet J, and Lisanti MP. Src tyrosine kinases, G alpha subunits and H-Ras share a common membrane-anchored scaffolding protein, Caveolin. Caveolin binding negatively regulates the auto-activation of Src tyrosine kinases. J Biol Chem 271: 29182-29190, 1996.
125. Li S, Galbiati F, Volonte D, Sargiacomo M, Engelman JA, Das K, Scherer PE, and Lisanti MP. Mutational analysis of caveolin-induced vesicle formation. Expression of caveolin-1 recruits caveolin-2 to caveolae membranes. FEBS Lett 434: 127-134, 1998.
126. Li S, Okamoto T, Chun M, Sargiacomo M, Casanova JE, Hansen SH, Nishimoto I, and Lisanti MP. Evidence for a regulated interaction of hetero-trimeric G proteins with caveolin. J Biol Chem 270: 15693-15701, 1995.
127. Li S, Seitz R, and Lisanti MP. Phosphorylation of caveolin by Src tyrosine kinases: the a-isoform of caveolin is selectively phosphorylated by v-Src in vivo. J Biol Chem 271: 3863-3868, 1996.
128. Li S, Song KS, Koh SS, Kikuchi A, and Lisanti MP. Baculovirus-based expression of mammalian caveolin in Sf21 insect cells. A model system for the biochemical and morphological study of caveolar biogenesis. J Biol Chem 271: 28647-28654, 1996.
129. Liou ML and Hsu CY. Japanese encephalitis virus is transported across the cerebral blood vessels by endocytosis in mouse brain. Cell Tissue Res 293: 389-394, 1998.
130. Lisanti MP, Scherer P, Tang ZL, and Sargiacomo M. Caveolae, caveolin and caveolin-rich membrane domains: a signalling hypothesis. Trends Cell Biol 4: 231-235, 1994.
131. Lisanti MP, Scherer PE, Vidugiriene J, Tang ZL, Hermanoski-Vosatka A, Tu YH, Cook RF, and Sargiacomo M. Characterization of caveolin-rich membrane domains isolated from an endothelial-rich source: implications for human disease. J Cell Biol 126: 111-126, 1994.
132. Lisanti MP, Tang ZT, Scherer P, and Sargiacomo M. Caveolae purification and GPI-linked protein sorting in polarized epithelia. Methods Enzymol 250: 655-668, 1995.
133. Liscovitch M and Lavie Y. Multidrug resistance: a role for cholesterol efflux pathways? Trends Biochem Sci 25: 530-534, 2000.
134. Liu J, Oh P, Horner T, Rogers RA, and Schnitzer JE. Organized endothelial cell surface signal transduction in caveolae distinct from glycosylphosphatidylinositol-anchored protein microdomains. J Biol Chem 272: 7211-7222, 1997.
135. Liu J, Wang XB, Park DS, and Lisanti MP. Caveolin-1 expression enhances endothelial capillary tubule formation. J Biol Chem 277: 10661-10668, 2002.
136. Liu P, Li WP, Machleidt T, and Anderson RG. Identification of caveolin-1 in lipoprotein particles secreted by exocrine cells. Nat Cell Biol 1: 369-375, 1999.
137. Liu P, Ying Y, Ko YG, and Anderson RGW. Localization of the PDGF-stimulated phosphorylation cascade to caveolae. J Biol Chem 271: 10299-10303, 1996.
138. Liu P, Ying Y, Zhao Y, Mundy DI, Zhu M, and Anderson RG. Chinese hamster ovary K2 cell lipid droplets appear to be metabolic organelles involved in membrane traffic. J Biol Chem 279: 3787-3792, 2004.
139. Liu P, Ying YS, and Anderson RGW. PDGF activates MAP kinase in isolated caveolae. Proc Natl Acad Sci USA 94: 13666-13670, 1997.
140. Loeb LA, Loeb KR, and Anderson JP. Multiple mutations and cancer. Proc Natl Acad Sci USA 100: 776-781, 2003.
141. Loewen CJ, Moritz OL, and Molday RS. Molecular characterization of peripherin-2 and rom-1 mutants responsible for digenic retinitis pigmentosa. J Biol Chem 276: 22388-22396, 2001.
142. Londos C, Brasaemle DL, Gruia-Gray J, Servetnick DA, Schultz CJ, Levin DM, and Kimmel AR. Perilipin: unique proteins associated with intracellular neutral lipid droplets in adipocytes and steroidogenic cells. Biochem Soc Trans 23: 611-615, 1995.
143. Londos C, Brasaemle DL, Schultz CJ, Adler-Wailes DC, Levin DM, Kimmel AR, and Rondinone CM. On the control of lipolysis in adipocytes. Ann NY Acad Sci 892: 155-168, 1999.
144. Lu X, Gruia-Gray J, Copeland NG, Gilbert DJ, Jenkins NA, Londos C, and Kimmel AR. The murine perilipin gene: the lipid droplet-associated perilipins derive from tissue-specific, mRNA splice variants and define a gene family of ancient origin. Mamm Genome 12: 741-749, 2001.
145. Luetterforst R, Stang E, Zorzi N, Carozzi A, Way M, and Parton RG. Molecular characterization of caveolin association with the Golgi complex: identification of a cis-Golgi targeting domain in the caveolin molecule. J Cell Biol 145: 1443-1459, 1999.
146. Maglione JE, Moghanaki D, Young LJ, Manner CK, Ellies LG, Joseph SO, Nicholson B, Cardiff RD, and MacLeod CL. Transgenic polyoma middle-T mice model premalignant mammary disease. Cancer Res 61: 8298-8305, 2001.
147. Martinez-Botas J, Anderson JB, Tessier D, Lapillonne A, Chang BH, Quast MJ, Gorenstein D, Chen KH, and Chan L. Absence of perilipin results in leanness and reverses obesity in Lepr(db/db) mice. Nat Genet 26: 474-479, 2000.
148. Matsuda C, Hayashi YK, Ogawa M, Aoki M, Murayama K, Nishino I, Nonaka I, Arahata K, and Brown RH Jr. The sarcolemmal proteins dysferlin and caveolin-3 interact in skeletal muscle. Hum Mol Genet 10: 1761-1766, 2001.
149. Mayor S and Rao M. Rafts: scale-dependent, active lipid organization at the cell surface. Traffic 5: 231-240, 2004.
150. Mazzoccoli G, Carughi S, De Cata A, Giuliani A, Masciale N, La Viola M, Puzzolante F, and Balzanelli M. Interstitial lung diseases. Recent Prog Med 94: 227-237, 2003.
151. McIntosh DP, Tan XY, Oh P, and Schnitzer JE. Targeting endothelium and its dynamic caveolae for tissue-specific transcytosis in vivo: a pathway to overcome cell barriers to drug and gene delivery. Proc Natl Acad Sci USA 99: 1996-2001, 2002.
152. McNally EM, de Sa Moreira E, Duggan DJ, Bonnemann CG, Lisanti MP, Lidov HG, Vainzof M, Passos-Bueno MR, Hoffman EP, Zatz M, and Kunkel LM. Caveolin-3 in muscular dystrophy. Hum Mol Genet 7: 871-877, 1998.
153. Merlini L, Carbone I, Capanni C, Sabatelli P, Tortorelli S, Sotgia F, Lisanti MP, Bruno C, and Minetti C. Familial isolated hyperCKaemia associated with a new mutation in the caveolin-3 (CAV-3) gene. J Neurol Neurosurg Psychiatry 73: 65-67, 2002.
154. Minetti C, Bado M, Broda P, Sotgia F, Bruno C, Galbiati F, Volonte D, Lucania G, Pavan A, Bonilla E, Lisanti MP, and Cordone G. Impairment of caveolae formation and T-system disorganization in human muscular dystrophy with caveolin-3 deficiency. Am J Pathol 160: 265-270, 2002.
155. Minetti C, Sotogia F, Bruno C, Scartezzini P, Broda P, Bado M, Masetti E, Mazzocco P, Egeo A, Donati MA, Volonte' D, Galbiati F, Cordone G, Bricarelli FD, Lisanti MP, and Zara F. Mutations in the caveolin-3 gene cause autosomal dominant limb-girdle muscular dystrophy. Nature Genet 18: 365-368, 1998.
156. Miura S, Gan JW, Brzostowski J, Parisi MJ, Schultz CJ, Londos C, Oliver B, and Kimmel AR. Functional conservation for lipid storage droplet association among Perilipin, ADRP, and TIP47 (PAT)-related proteins in mammals, Drosophila, and Dictyostelium. J Biol Chem 277: 32253-32257, 2002.
157. Moller DE, Yokota A, Ginsberg-Fellner F, and Flier JS. Functional properties of a naturally occurring Trp1200-Ser1200 mutation of the insulin receptor. Mol Endocrinol 4: 1183-1191, 1990.
158. Moller DE, Yokota A, White MF, Pazianos AG, and Flier JS. A naturally occurring mutation of insulin receptor alanine 1134 impairs tyrosine kinase function and is associated with dominantly inherited insulin resistance. J Biol Chem 265: 14979-14985, 1990.
159. Monier S, Parton RG, Vogel F, Behlke J, Henske A, and Kurzchalia T. VIP21-caveolin, a membrane protein constituent of the caveolar coat, oligomerizes in vivo and in vitro. Mol Biol Cell 6: 911-927, 1995.
160. Mora R, Bonilha VL, Marmorstein A, Scherer PE, Brown D, Lisanti MP, and Rodriguez-Boulan E. Caveolin-2 localizes to the Golgi complex but redistributes to plasma membrane, caveolae, and rafts when co-expressed with caveolin-1. J Biol Chem 274: 25708-25717, 1999.
161. Mordue DG, Desai N, Dustin M, and Sibley LD. Invasion by Toxoplasma gondii establishes a moving junction that selectively excludes host cell plasma membrane proteins on the basis of their membrane anchoring. J Exp Med 190: 1783-1792, 1999.
162. Mouraviev V, Li L, Tahir SA, Yang G, Timme TM, Goltsov A, Ren C, Satoh T, Wheeler TM, Ittmann MM, Miles BJ, Amato RJ, Kadmon D, and Thompson TC. The role of caveolin-1 in androgen insensitive prostate cancer. J Urol 168: 1589-1596, 2002.
163. Muller G, Hanekop N, Wied S, and Frick W. Cholesterol depletion blocks redistribution of lipid raft components and insulin-mimetic signaling by glimepiride and phosphoinositolglycans in rat adipocytes. Mol Med 8: 120-136, 2002.
164. Mundy DI, Machleidt T, Ying YS, Anderson RG, and Bloom GS. Dual control of caveolar membrane traffic by microtubules and the actin cytoskeleton. J Cell Sci 115: 4327-4339, 2002.
165. Munro S. Lipid rafts: elusive or illusive? Cell 115: 377-388, 2003.
166. Nguyen DH and Hildreth JE. Evidence for budding of human immunodeficiency virus type 1 selectively from glycolipid-enriched membrane lipid rafts. J Virol 74: 3264-3272, 2000.
167. Nielsen MH and Settnes OP. Morphology of Pneumocystis carinii and activation of the plasmalemmal vesicular system in alveolar epithelial cells of the host. An ultrastractural study. Apmis 99: 219-225, 1991.
168. Nordestgaard BG. The vascular endothelial barrier-selective retention of lipoproteins. Curr Opin Lipidol 7: 269-273, 1996.
169. Norkin LC. Simian virus 40 infection via MHC class I molecules and caveolae. Immunol Rev 168: 13-22, 1999.
170. Norkin LC. Caveolae in the uptake and targeting of infectious agents and secreted toxins. Adv Drug Deliv Rev 49: 301-315, 2001.
171. Norkin LC, Anderson HA, Wolfrom SA, and Oppenheim A. Caveolar endocytosis of simian virus 40 is followed by brefeldin A-sensitive transport to the endoplasmic reticulum, where the virus disassembles. J Virol 76: 5156-5166, 2002.
172. Nystrom FH, Chen H, Cong LN, Li Y, and Quon MJ. Caveolin-1 interacts with the insulin receptor and can differentially modulate insulin signaling in transfected Cos-7 cells and rat adipose cells. Mol Endocrinol 13: 2013-2024, 1999.
173. Oh P, McIntosh DP, and Schnitzer JE. Dynamin at the neck of caveolae mediates their budding to form transport vesicles by GTP-driven fission from the plasma membrane of endothelium. J Cell Biol 141: 101-114, 1998.
174. Ohashi M, Mizushima N, Kabeya Y, and Yoshimori T. Localization of mammalian NAD(P)H steroid dehydrogenase-like protein on lipid droplets. J Biol Chem 278: 36819-36829, 2003.
175. Ohsawa Y, Toko H, Katsura M, Morimoto K, Yamada H, Ichikawa Y, Murakami T, Ohkuma S, Komuro I, and Sunada Y. Overexpression of P104L mutant caveolin-3 in mice develops hypertrophic cardiomyopathy with enhanced contractility in association with increased endothelial nitric oxide synthase activity. Hum Mol Genet 13: 151-157, 2004.
176. Okamoto T, Schlegel A, Scherer PE, and Lisanti MP. Caveolins, a family of scaffolding proteins for organizing "preassembled signaling complexes" at the plasma membrane. J Biol Chem 273: 5419-5422, 1998.
177. Orlandi PA and Fishman PH. Filipin-dependent inhibition of cholera toxin: evidence for toxin internalization and activation through caveolae-like domains. J Cell Biol 141: 905-915, 1998.
178. Ostermeyer AG, Paci JM, Zeng Y, Lublin DM, Munro S, and Brown DA. Accumulation of caveolin in the endoplasmic reticulum redirects the protein to lipid storage droplets. J Cell Biol 152: 1071-1078, 2001.
179. Ostermeyer AG, Ramcharan LT, Zeng Y, Lublin DM, and Brown DA. Role of the hydrophobic domain in targeting caveolin-1 to lipid droplets. J Cell Biol 164: 69-78, 2004.
180. Pacione LR, Szego MJ, Ikeda S, Nishina PM, and McInnes RR. Progress toward understanding the genetic and biochemical mechanisms of inherited photoreceptor degenerations. Annu Rev Neurosci 26: 657-700, 2003.
181. Palade GE. Fine structure of blood capillaries. J Appl Physiol 24: 1424, 1953.
182. Park DS, Cohen AW, Frank PG, Razani B, Lee H, Williams TM, Chandra M, Shirani J, Pereira de Souza A, Tang B, Jelicks LA, Factor SM, Weiss LM, Tanowitz HB, and Lisanti MP. Caveolin-1 null (-/-) mice show dramatic reductions in life span. Biochemistry 42: 15124-15131, 2003.
183. Park DS, Razani B, Lasorella A, Schreiber-Agus N, Pestell RG, Iavarone A, and Lisanti MP. Evidence that Myc isoforms transcriptionally repress caveolin-1 gene expression via an INR-dependent mechanism. Biochemistry 40: 3354-3362, 2001.
184. Park DS, Woodman SE, Schubert W, Cohen AW, Frank PG, Chandra M, Shirani J, Razani B, Tang B, Jelicks LA, Factor SM, Weiss LM, Tanowitz HB, and Lisanti MP. Caveolin-1/3 double-knockout mice are viable, but lack both muscle and non-muscle caveolae, and develop a severe cardiomyopathic phenotype. Am J Pathol 160: 2207-2217, 2002.
185. Parolini I, Sargiacomo M, Galbiati F, Rizzo G, Grignani F, Engelman JA, Okamoto T, Ikezu T, Scherer PE, Mora R, Rodriguez-Boulan E, Peschle C, and Lisanti MP. Expression of caveolin-1 is required for the transport of caveolin-2 to the plasma membrane. Retention of caveolin-2 at the level of the Golgi complex. J Biol Chem 274: 25718-25725, 1999.
186. Parpal S, Karlsson M, Thorn H, and Stralfors P. Cholesterol depletion disrupts caveolae and insulin receptor signaling for metabolic control via insulin receptor substrate-1, but, not for mitogen-activated protein kinase control. J Biol Chem 276: 9670-9678, 2001.
187. Parton RG and Hancock JF. Lipid rafts and plasma membrane microorganization: insights from Ras. Trends Cell Biol 14: 141-147, 2004.
188. Parton RG, Joggerst B, and Simons K. Regulated internalization of caveolae. J Cell Biol 127: 1199-1215, 1994.
189. Parton RG, Way M, Zorzi N, and Stang E. Caveolin-3 associates with developing T-tubules during muscle differentiation. J Cell Biol 136: 137-154, 1997.
190. Pelkmans L and Helenius A. Endocytosis via caveolae. Traffic 3: 311-320, 2002.
191. Pelkmans L, Kartenbeck J, and Helenius A. Caveolar endocytosis of simian virus 40 reveals a new two-step vesicular-transport pathway to the ER. Nat Cell Biol 3: 473-483, 2001.
192. Pelkmans L, Puntener D, and Helenius A. Local actin polymerization and dynamin recruitment in SV40-induced internalization of caveolae. Science 296: 535-539, 2002.
193. Peyron P, Bordier C, N'Diaye EN, and Maridonneau-Parini I. Nonopsonic phagocytosis of Mycobacterium kansasii by human neutrophils depends on cholesterol and is mediated by CR3 associated with glycosylphosphatidylinositol- anchored proteins. J Immunol 165: 5186-5191, 2000.
194. Plump AS, Smith JD, Hayek T, Aalto-Setala K, Walsh A, Verstuyft JG, Rubin EM, and Breslow JL. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell 71: 343-353, 1992.
195. Pol A, Luetterforst R, Lindsay M, Heino S, Ikonen E, and Parton RG. A caveolin dominant negative mutant associates with lipid bodies and induces intracellular cholesterol imbalance. J Cell Biol 152: 1057-1070, 2001.
196. Razani B, Altschuler Y, Zhu L, Pestell RG, Mostov KE, and Lisanti MP. Caveolin-1 expression is down-regulated in cells transformed by the human papilloma virus in a p53-dependent manner. Replacement Of caveolin-1 expression suppresses HPV-mediated cell transformation. Biochemistry 39: 13916-13924, 2000.
197. Razani B, Combs TP, Wang XB, Frank PG, Park DS, Russell RG, Li M, Tang B, Jelicks LA, Scherer PE, and Lisanti MP. Caveolin-1-deficient mice are lean, resistant to diet-induced obesity, and show hypertriglyceridemia with adipocyte abnormalities. J Biol Chem 277: 8635-8647, 2002.
198. Razani B, Engelman JA, Wang XB, Schubert W, Zhang XL, Marks CB, Macaluso F, Russell RG, Li M, Pestell RG, Di Vizio D, Hou H Jr, Kneitz B, Lagaud G, Christ GJ, Edelmann W, and Lisanti MP. Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities. J Biol Chem 276: 38121-38138, 2001.
199. Razani B, Wang XB, Engelman JA, Battista M, Lagaud G, Zhang XL, Kneitz B, Hou H Jr, Christ GJ, Edelmann W, and Lisanti MP. Caveolin-2-deficient mice show evidence of severe pulmonary dysfunction without disruption of caveolae. Mol Cell Biol 22: 2329-2344, 2002.
200. Razani B, Woodman SE, and Lisanti MP. Caveolae: from cell biology to animal physiology. Pharmacol Rev 54: 431-467, 2002.
201. Repetto S, Bado M, Broda P, Lucania G, Masetti E, Sotgia F, Carbone I, Pavan A, Bonilla E, Cordone G, Lisanti MP, and Minetti C. Increased number of caveolae and caveolin-3 overexpression in Duchenne muscular dystrophy. Biochem Biophys Res Commun 261: 547-550, 1999.
202. Ricci V, Galmiche A, Doye A, Necchi V, Solcia E, and Boquet P. High cell sensitivity to Helicobacter pylori VacA toxin depends on a GPI-anchored protein and is not blocked by inhibition of the clathrin-mediated pathway of endocytosis. Mol Biol Cell 11: 3897-3909, 2000.
203. Rothberg KG, Heuser JE, Donzell WC, Ying Y, Glenney JR, and Anderson RGW. Caveolin, a protein component of caveolae membrane coats. Cell 68: 673-682, 1992.
204. Roy S, Luetterforst R, Harding A, Apolloni A, Etheridge M, Stang E, Rolls B, Hancock JF, and Parton RG. Dominant-negative caveolin inhibits H-Ras function by disrupting cholesterol-rich plasma membrane domains. Nat Cell Biol 1: 98-105, 1999.
205. Runte M, Dekomien G, and Epplen JT. Evaluation of RDS/Peripherin and ROM1 as candidate genes in generalised progressive retinal atrophy and exclusion of digenic inheritance. Anim Genet 31: 223-227, 2000.
206. Rybin VO, Grabham PW, Elouardighi H, and Steinberg SF. Caveolae-associated proteins in cardiomyocytes: caveolin-2 expression and interactions with caveolin-3. Am J Physiol Heart Circ Physiol 285: H325-H332, 2003.
207. Rybin VO, Xu X, Lisanti MP, and Steinberg SF. Differential targeting of beta-adrenergic receptor subtypes and adenylyl cyclase to cardiomyocyte caveolae. A mechanism to functionally regulate the cAMP signaling pathway. J Biol Chem 275: 41447-41457, 2000.
208. Rybin VO, Xu X, and Steinberg SF. Activated protein kinase C isoforms target to cardiomyocyte caveolae: stimulation of local protein phosphorylation. Circ Res 84: 980-988, 1999.
209. Sager R, Sheng S, Anisowicz A, Sotiropoulou G, Zou Z, Stenman G, Swisshelm K, Chen Z, Hendrix MJC, Pemberton P, Rafidi K, and Ryan K. RNA genetics of breast cancer maspin as a paradigm. Cold Spring Harbor Sym Quant Biol LIX: 537-546, 1994.
210. Salzer U and Prohaska R. Stomatin, flotillin-1, and flotillin-2 are major integral proteins of erythrocyte lipid rafts. Blood 97: 1141-1143, 2001.
211. Sargiacomo M, Scherer PE, Tang ZL, Kubler E, Song KS, Sanders MC, and Lisanti MP. Oligomeric structure of caveolin: implications for caveolae membrane organization. Proc Natl Acad Sci USA 92: 9407-9411, 1995.
212. Sargiacomo M, Sudol M, Tang ZL, and Lisanti W. Signal transducing molecules and GPI-linked proteins form a caveolin-rich insoluble complex in MDCK cells. J Cell Biol 122: 789-807, 1993.
213. Sawa T, Imamura T, Haruta T, Sasaoka T, Ishiki M, Takata Y, Takada Y, Morioka H, Ishihara H, Usui I, and Kobayashi M. Hsp70 family molecular chaperones and mutant insulin receptor: differential binding specificities of BiP and Hsp70/Hsc70 determines accumulation or degradation of insulin receptor. Biochem Biophys Res Commun 218: 449-453, 1996.
214. Scherer PE, Lewis RY, Volonte D, Engelman JA, Galbiati F, Couet J, Kohtz DS, van Donselaar E, Peters P, and Lisanti MP. Cell-type and tissue-specific expression of caveolin-2. Caveolins 1 and 2 co-localize and form a stable hetero-oligomeric complex in vivo. J Biol Chem 272: 29337-29346, 1997.
215. Scherer PE, Lisanti MP, Baldini G, Sargiacomo M, Corley-Mastick C, and Lodish HF. Induction of caveolin during adipogenesis and association of GLUT4 with caveolin-rich vesicles. J Cell Biol 127: 1233-1243, 1994.
216. Scherer PE, Okamoto T, Chun M, Nishimoto I, Lodish HF, and Lisanti MP. Identification sequence and expression of caveolin-2 defines a caveolin gene family. Proc Natl Acad Sci USA 93: 131-135, 1996.
217. Scherer PE, Tang ZL, Chun MC, Sargiacomo M, Lodish HF, and Lisanti MP. Caveolin isoforms differ in their N-terminal protein sequence and subcellular distribution: identification and epitope mapping of an isoform-specific monoclonal antibody probe. J Biol Chem 270: 16395-16401, 1995.
218. Schlegel A, Arvan P, and Lisanti MP. Caveolin-1 binding to endoplasmic reticulum membranes and entry into the regulated secretory pathway are regulated by serine phosphorylation. Protein sorting at the level of the endoplasmic reticulum. J Biol Chem 276: 4398-4408, 2001.
219. Schlegel A and Lisanti MP. Caveolins in cholesterol trafficking and signal transduction: implications for human disease. Front Biosci 5: 929-937, 2000.
220. Schlegel A and Lisanti MP. A molecular dissection of caveolin-1 membrane attachment and oligomerization. Two separate regions of the caveolin-1 C-terminal domain mediate membrane binding and oligomer/oligomer interactions in vivo. J Biol Chem 275: 21605-21617, 2000.
221. Schlegel A, Schwab R, Scherer PE, and Lisanti MP. A role for the caveolin scaffolding domain in mediating the membrane attachment of caveolin-1. The caveolin scaffolding domain is both necessary and sufficient for membrane binding in vitro. J Biol Chem 274: 22660-22667, 1999.
222. Schnitzer JE, Liu J, and Oh P. Endothelial caveolae have the molecular transport machinery for vesicle budding, docking, and fusion including VAMP, NSF, SNAP, annexins, and GTPases. J Biol Chem 270: 14399-14404, 1995.
223. Schroeder R, London E, and Brown D. Interactions between saturated acyl chains confer detergent resistance on lipids and glycosylphosphatidylinositol (GPI)-anchored proteins: GPI-anchored proteins in liposomes and cells show similar behavior. Proc Natl Acad Sci USA 91: 12130-12134, 1994.
224. Schubert W, Frank PG, Razani B, Park DS, Chow CW, and Lisanti MP. Caveolae-deficient endothelial cells show defects in the uptake and transport of albumin in vivo. J Biol Chem 276: 48619-48622, 2001.
225. Schubert W, Frank PG, Woodman SE, Hyogo H, Cohen DE, Chow CW, and Lisanti MP. Microvascular hyperpermeability in caveolin-1 (-/-) knock-out mice. Treatment with a specific nitric-oxide synthase inhibitor, L-NAME, restores normal microvascular permeability in Cav-1 null mice. J Biol Chem 277: 40091-40098, 2002.
226. Schwartz JH. The many dimensions of cAMP signaling. Proc Natl Acad Sci USA 98: 13482-13484, 2001.
227. Sciandra F, Bozzi M, Bianchi M, Pavoni E, Giardina B, and Brancaccio A. Dystroglycan and muscular dystrophies related to the dystrophin-glycoprotein complex. Ann Ist Super Sanita 39: 173-181, 2003.
228. Scidmore MA, Rockey DD, Fischer ER, Heinzen RA, and Hackstadt T. Vesicular interactions of the Chlamydia trachomatis inclusion are determined by chlamydial early protein synthesis rather than route of entry. Infect Immun 64: 5366-5372, 1996.
229. Selvarangan R, Goluszko P, Popov V, Singhal J, Pham T, Lublin DM, Nowicki S, and Nowicki B. Role of decay-accelerating factor domains and anchorage in internalization of Dr-fimbriated Escherichia coli. Infect Immun 68: 1391-1399, 2000.
230. Settnes OP and Nielsen MJ. Host-parasite relationship in Pneumocystis carinii infection: activation of the plasmalemmal vesicular system in type I alveolar epithelial cells. J Protozool 38: 174S-176S, 1991.
231. Shin JS and Abraham SN. Caveolae as portals of entry for microbes. Microbes Infect 3: 755-761, 2001.
232. Shin JS, Gao Z, and Abraham SN. Involvement of cellular caveolae in bacterial entry into mast cells. Science 289: 785-788, 2000.
233. Simionescu N, Simionescu M, and Palade GE. Permeability of muscle capillaries to small heme-peptides: evidence for the existence of patent transendothelial channels. J Cell Biol 64: 586-607, 1975.
234. Simons K and Toomre D. Lipid rafts and signal transduction. Nat Rev Mol Cell Biol 1: 31-39, 2000.
235. Singer SJ and Nicolson GL. The fluid mosaic model of the structure of cell membranes. Science 175: 720-731, 1972.
236. Sinn PL, Hickey MA, Staber PD, Dylla DE, Jeffers SA, Davidson BL, Sanders DA, and McCray PB Jr. Lentivirus vectors pseudotyped with filoviral envelope glycoproteins transduce airway epithelia from the apical surface independently of folate receptor alpha. J Virol 77: 5902-5910, 2003.
237. Smart E, Ying YS, Conrad P, and Anderson RGW. Caveolin moves from caveolae to the Golgi apparatus in response to cholesterol oxidation. J Cell Biol 127: 1185-1197, 1994.
238. Smart EJ, Ying Y, Mineo C, and Anderson RGW. A detergent free method for purifying caveolae membrane from tissue cultured cells. Proc Natl Acad Sci USA 92: 10104-10108, 1995.
239. Smythe GM, Eby JC, Disatnik MH, and Rando TA. A caveolin-3 mutant that causes limb girdle muscular dystrophy type 1C disrupts Src localization and activity and induces apoptosis in skeletal myotubes. J Cell Sci 116: 4739-4749, 2003.
240. Snyers L, Umlauf E, and Prohaska R. Association of stomatin with lipid-protein complexes in the plasma membrane and the endocytic compartment. Eur J Cell Biol 78: 802-812, 1999.
241. Song KS, Li S, Okamoto T, Quilliam L, Sargiacomo M, and Lisanti MP. Copurification and direct interaction of Ras with caveolin, an integral membrane protein of caveolae microdomains. Detergent free purification of caveolae membranes. J Biol Chem 271: 9690-9697, 1996.
242. Song KS, Scherer PE, Tang Z, Okamoto T, Li S, Chafel M, Chu C, Kohtz DS, and Lisanti MP. Expression of caveolin-3 in skeletal, cardiac, and smooth muscle cells. Caveolin-3 is a component of the sarcolemma and co-fractionates with dystrophin and dystrophin-associated glycoproteins. J Biol Chem 271: 15160-15165, 1996.
243. Song KS, Tang ZL, Li S, and Lisanti MP. Mutational analysis of the properties of caveolin-1. A novel role for the C-terminal domain in mediating homotypic caveolin-caveolin interactions. J Biol Chem 272: 4398-4403, 1997.
244. Sotgia F, Bonuccelli G, Minetti C, Woodman SE, Capozza F, Kemp RG, Scherer PE, and Lisanti MP. Phosphofructokinase muscle-specific isoform requires caveolin-3 expression for plasma membrane recruitment and caveolar targeting: implications for the pathogenesis of caveolin-related muscle diseases. Am J Pathol 163: 2619-2634, 2003.
245. Sotgia F, Lee JK, Das K, Bedford M, Petrucci TC, Macioce P, Sargiacomo M, Bricarelli FD, Minetti C, Sudol M, and Lisanti MP. Caveolin-3 directly interacts with the C-terminal tail of beta-dystroglycan. Identification of a central WW-like domain within caveolin family members. J Biol Chem 275: 38048-38058, 2000.
246. Sotgia F, Woodman SE, Bonuccelli G, Capozza F, Minetti C, Scherer PE, and Lisanti MP. Phenotypic behavior of caveolin-3 R26Q, a mutant associated with hyperCKemia, distal myopathy, and rippling muscle disease. Am J Physiol Cell Physiol 285: C1150-C1160, 2003.
247. Sprenger RR, Speijer D, Back JW, De Koster CG, Pannekoek H, and Horrevoets AJ. Comparative proteomics of human endothelial cell caveolae and rafts using two-dimensional gel electrophoresis and mass spectrometry electrophoresis. Electrophoresis 25: 156-172, 2004.
248. Stefaniak AB, Weaver VM, Cadorette M, Puckett LG, Schwartz BS, Wiggs LD, Jankowski MD, and Breysse PN. Summary of historical beryllium uses and airborne concentration levels at Los Alamos National Laboratory. Appl Occup Environ Hyg 18: 708-715, 2003.
249. Su CL, Sztalryd C, Contreras JA, Holm C, Kimmel AR, and Londos C. Mutational analysis of the hormone-sensitive lipase translocation reaction in adipocytes. J Biol Chem. In press.
250. Sukumaran SK, Quon MJ, and Prasadarao NV. Escherichia coli K1 internalization via caveolae requires caveolin-1 and protein kinase Calpha interaction in human brain microvascular endothelial cells. J Biol Chem 277: 50716-50724, 2002.
251. Sunada Y, Ohi H, Hase A, Hosono T, Arata S, Higuchi S, Matsumura K, and Shimizu T. Transgenic mice expressing mutant caveolin-3 show severe myopathy associated with increased nNOS activity. Hum Mol Genet 10: 173-178, 2001.
252. Suzuoki M, Miyamoto M, Kato K, Hiraoka K, Oshikiri T, Nakakubo Y, Fukunaga A, Shichinohe T, Shinohara T, Itoh T, Kondo S, and Katoh H. Impact of caveolin-1 expression on prognosis of pancreatic ductal adenocarcinoma. Br J Cancer 87: 1140-1144, 2002.
253. Syu LJ and Saltiel AR. Lipotransin: a novel docking protein for hormone-sensitive lipase. Mol Cell 4: 109-115, 1999.
254. Sztalryd C, Xu G, Dorward H, Tansey JT, Contreras JA, Kimmel AR, and Londos C. Perilipin A is essential for the translocation of hormone-sensitive lipase during lipolytic activation. J Cell Biol 161: 1093-1103, 2003.
255. Tahir SA, Yang G, Ebara S, Timme TL, Satoh T, Li L, Goltsov A, Ittmann M, Morrisett JD, and Thompson TC. Secreted caveolin-1 stimulates cell survival/clonal growth and contributes to metastasis in androgen-insensitive prostate cancer. Cancer Res 61: 3882-3885, 2001.
256. Tang ZL, Scherer PE, Okamoto T, Song K, Chu C, Kohtz DS, Nishimoto I, Lodish HF, and Lisanti MP. Molecular cloning of caveolin-3, a novel member of the caveolin gene family expressed predominantly in muscle. J Biol Chem 271: 2255-2261, 1996.
257. Tansey JT, Sztalryd C, Gruia-Gray J, Roush DL, Zee JV, Gavrilova O, Reitman ML, Deng CX, Li C, Kimmel AR, and Londos C. Perilipin ablation results in a lean mouse with aberrant adipocyte lipolysis, enhanced leptin production, and resistance to diet-induced obesity. Proc Natl Acad Sci USA 98: 6494-6499, 2001.
258. Than NG, Sumegi B, Bellyei S, Berki T, Szekeres G, Janaky T, Szigeti A, Bohn H, and Than GN. Lipid droplet and milk lipid globule membrane associated placental protein 17b (PP17b) is involved in apoptotic and differentiation processes of human epithelial cervical carcinoma cells. Eur J Biochem 270: 1176-1188, 2003.
259. Thompson TC, Timme TL, Li L, and Goltsov A. Caveolin-1, a metastasis-related gene that promotes cell survival in prostate cancer. Apoptosis 4: 233-237, 1999.
260. Thomsen P, Roepstorff K, Stahlhut M, and van Deurs B. Caveolae are highly immobile plasma membrane microdomains, which are not involved in constitutive endocytic trafficking. Mol Biol Cell 13: 238-250, 2002.
261. Torbergsen T. Rippling muscle disease: a review. Muscle Nerve Suppl 11: S103-S107, 2002.
262. Vaghy PL, Fang J, Wu W, and Vaghy LP. Increased caveolin-3 levels in mdx mouse muscles. FEBS Lett 431: 125-127, 1998.
263. Van Meer G and Burger KN. Sphingolipid trafficking-sorted out? Trends Cell Biol 2: 332-337, 1992.
264. Van Meer G, Stelzer EHK, Wijnaendts-van Resandt RW, and Simons K. Sorting of sphingolipids in epithelial (Madin-Darby canine kidney) cells. J Cell Biol 105: 1623-1635, 1987.
265. Vasile E, Simionescu M, and Simionescu N. Visualization of the binding, endocytosis, and transcytosis of low density lipoprotein in the arterial endothelium in situ. J Cell Biol 96: 1677-1689, 1983.
266. Venema VJ, Ju H, Zou R, and Venema RC. Interaction of neuronal nitric-oxide synthase with caveolin-3 in skeletal muscle. Identification of a novel caveolin scaffolding/inhibitory domain. J Biol Chem 272: 28187-28190, 1997.
267. Vey M, Pilkuhn S, Holger W, Nixon R, DeArmond SJ, Smart EJ, Anderson RGW, Taraboulos A, and Prusiner SB. Subcellular localization of the scrapie prion proteins in caveolae-like membranous domains. Proc Natl Acad Sci USA 93: 14945-14949, 1996.
268. Vey M, Pilkuhn S, Wille H, Nixon R, DeArmond SJ, Smart EJ, Anderson RG, Taraboulos A, and Prusiner SB. Subcellular colocalization of the cellular and scrapie prion proteins in lae-like membranous domains. Proc Natl Acad Sci USA 93: 14945-14949, 1996.
269. Volonte D, Galbiati F, Li S, Nishiyama K, Okamoto T, and Lisanti MP. Flotillins/cavatellins are differentially expressed in cells and tissues and form a hetero-oligomeric complex with caveolins in vivo. Characterization and epitope-mapping of a novel flotillin-1 monoclonal antibody probe. J Biol Chem 274: 12702-12709, 1999.
270. Wang PY, Kitchens RL, and Munford RS. Bacterial lipopolysaccharide binds to CD14 in low-density domains of the monocyte-macrophage plasma membrane. J Inflamm 47: 126-137, 1995.
271. Ward T, Powell RM, Pipkin PA, Evans DJ, Minor PD, and Almond JW. Role for beta2-microglobulin in echovirus infection of rhabdomyosarcoma cells. J Virol 72: 5360-5365, 1998.
272. Way M and Parton R. M-caveolin, a muscle-specific caveolin-related protein. FEBS Lett 376: 108-112, 1995.
273. Werling D, Hope JC, Chaplin P, Collins RA, Taylor G, and Howard CJ. Involvement of caveolae in the uptake of respiratory syncytial virus antigen by dendritic cells. J Leukoc Biol 66: 50-58, 1999.
274. Williams TM, Cheung MW, Park DS, Razani B, Cohen AW, Muller WJ, Di Vizio D, Chopra NG, Pestell RG, and Lisanti MP. Loss of caveolin-1 gene expression accelerates the development of dysplastic mammary lesions in tumor-prone transgenic mice. Mol Biol Cell 14: 1027-1042, 2003.
275. Wolins NE, Rubin B, and Brasaemle DL. TIP47 associates with lipid droplets. J Biol Chem 276: 5101-5108, 2001.
276. Wolins NE, Skinner JR, Schoenfish MJ, Tzekov A, Bensch KG, and Bickel PE. Adipocyte protein S3-12 coats nascent lipid droplets. J Biol Chem 278: 37713-37721, 2003.
277. Woodman SE, Ashton AW, Schubert W, Lee H, Williams TM, Medina FA, Wyckoff JB, Combs TP, and Lisanti MP. Caveolin-1 knockout mice show an impaired angiogenic response to exogenous stimuli. Am J Pathol 162: 2059-2068, 2003.
278. Woodman SE, Cheung MW, Tarr M, North AC, Schubert W, Lagaud G, Marks CB, Russell RG, Hassan GS, Factor SM, Christ GJ, and Lisanti MP. Urogenital alterations in aged male caveolin-1 knockout mice. J Urol 171: 950-957, 2004.
279. Woodman SE, Park DS, Cohen AW, Cheung MW, Chandra M, Shirani J, Tang B, Jelicks LA, Kitsis RN, Christ GJ, Factor SM, Tanowitz HB, and Lisanti MP. Caveolin-3 knock-out mice develop a progressive cardiomyopathy and show hyperactivation of the p42/44 MAPK cascade. J Biol Chem 277: 38988-38997, 2002.
280. Woodman SE, Schlegel A, Cohen AW, and Lisanti MP. Mutational analysis identifies a short atypical membrane attachment sequence (KYWFYR) within caveolin-1. Biochemistry 41: 3790-3795, 2002.
281. Wooldridge KG, Williams PH, and Ketley JM. Host signal transduction and endocytosis of Campylobacter jejuni. Microb Pathogenesis 21: 299-305, 1996.
282. Wu D and Terrian DM. Regulation of caveolin-1 expression and secretion by a protein kinase C (PKC) epsilon signaling pathway in human prostate cancer cells. J Biol Chem 277: 40449-40455, 2002.
283. Xaubet A, Marin-Arguedas A, Lario S, Ancochea J, Morell F, Ruiz-Manzano J, Rodriguez-Becerra E, Rodriguez-Arias JM, Inigo P, Sanz S, Campistol JM, Mullol J, and Picado C. Transforming growth factor-beta1 gene polymorphisms are associated with disease progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 168: 431-435, 2003.
284. Yabe I, Kawashima A, Kikuchi S, Higashi T, Fukazawa T, Hamada T, Sasaki H, and Tashiro K. Caveolin-3 gene mutation in Japanese with rippling muscle disease. Acta Neurol Scand 108: 47-51, 2003.
285. Yamada E. The fine structure of the gall bladder epithelium of the mouse. J Biophys Biochem Cytol 1: 445-458, 1955.
286. Yamamoto M, Toya Y, Schwencke C, Lisanti MP, Myers M, and Ishikawa Y. Caveolin is an activator of insulin receptor signaling. J Biol Chem 273: 26962-26968, 1998.
287. Yang CP, Galbiati F, Volonte D, Horwitz SB, and Lisanti MP. Upregulation of caveolin-1 and caveolae organelles in Taxol-resistant A549 cells. FEBS Lett 439: 368-372, 1998.
288. Yang G, Truong LD, Timme TL, Ren C, Wheeler TM, Park SH, Nasu Y, Bangma CH, Kattan MW, Scardino PT, and Thompson TC. Elevated expression of caveolin is associated with prostate and breast cancer. Clin Cancer Res 4: 1873-1880, 1998.
289. Zenklusen JC, Thompson JC, Klein-Szanto AJ, and Conti CJ. Frequent loss of heterozygosity in human primary squamous cell and colon carcinomas at 7q31.1: evidence for a broad range tumor suppressor gene. Cancer Res 55: 1347-1350, 1995.
290. Zenklusen JC, Thompson JC, Troncoso P, Kagan J, and Conti CJ. Loss of heterozygosity in human primary prostate carcinomas: a possible tumor suppressor gene at 7q31.1. Cancer Res 54: 6370-6373, 1994.
291. Zenklusen JC, Weitzel JN, Ball HG, and Conti CJ. Allelic loss at 7q31.1 in human primary ovarian carcinomas suggests the existence of a tumor suppressor gene. Oncogene 11: 359-363, 1995.
292. Zhang W, Razani B, Altschuler Y, Bouzahzah B, Mostov KE, Pestell RG, and Lisanti MP. Caveolin-1 inhibits epidermal growth factor-stimulated lamellipod extension and cell migration in metastatic mammary adenocarcinoma cells (MTLn3). Transformation suppressor effects of adenovirus-mediated gene delivery of caveolin-1. J Biol Chem 275: 20717-20725, 2000.
293. Zhao YY, Liu Y, Stan RV, Fan L, Gu Y, Dalton N, Chu PH, Peterson K, Ross J Jr, and Chien KR. Defects in caveolin-1 cause dilated cardiomyopathy and pulmonary hypertension in knockout mice. Proc Natl Acad Sci USA 99: 11375-11380, 2002.